{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioblastoma%2C+IDH-Wildtype",
    "query": {
      "condition": "Glioblastoma, IDH-Wildtype"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 54,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioblastoma%2C+IDH-Wildtype&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-21T23:49:28.745Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06860594",
      "title": "Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Astrocytoma, IDH-Mutant, Grade 2",
        "Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant",
        "Recurrent Adult Diffuse Midline Glioma, H3 K27-Mutant",
        "Recurrent Astrocytoma, IDH-Mutant",
        "Recurrent Astrocytoma, IDH-Mutant, Grade 3",
        "Recurrent Astrocytoma, IDH-Mutant, Grade 4",
        "Recurrent Glioblastoma, IDH-Wildtype"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Triapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2025-07-30",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-05-21T23:49:28.745Z",
      "location_count": 42,
      "location_summary": "Duarte, California • Irvine, California • La Jolla, California + 33 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06860594"
    },
    {
      "nct_id": "NCT07386002",
      "title": "The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype"
      ],
      "interventions": [
        {
          "name": "Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "T-MAXIMUM Pharmaceutical Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 40,
      "start_date": "2026-06-30",
      "completion_date": "2029-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-10",
      "last_synced_at": "2026-05-21T23:49:28.745Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07386002"
    },
    {
      "nct_id": "NCT04145115",
      "title": "A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Astrocytoma, IDH-Mutant, Grade 4",
        "Diffuse Glioma",
        "Glioblastoma, IDH-Wildtype",
        "Secondary Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2020-12-24",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-05-21T23:49:28.745Z",
      "location_count": 415,
      "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 289 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04145115"
    },
    {
      "nct_id": "NCT03423628",
      "title": "A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Glioblastoma Multiforme",
        "Primary Glioblastoma Multiforme",
        "Brain Neoplasms, Malignant",
        "Leptomeningeal Disease (LMD)"
      ],
      "interventions": [
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "AZD1390",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 180,
      "start_date": "2018-04-02",
      "completion_date": "2026-09-16",
      "has_results": false,
      "last_update_posted_date": "2025-12-22",
      "last_synced_at": "2026-05-21T23:49:28.745Z",
      "location_count": 5,
      "location_summary": "Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03423628"
    },
    {
      "nct_id": "NCT07223034",
      "title": "A Study of 177Lu-PSMA-617 in People With Gliomas",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioma",
        "Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4)",
        "Glioblastoma, IDH-wildtype",
        "Diffuse Midline Glioma, H3 K27-Altered",
        "Diffuse Hemispheric Glioma, H3 G34-mutant",
        "Diffuse Pediatric-type High-grade Glioma, H3-wildtype and IDH-wildtype"
      ],
      "interventions": [
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "177Lu-PSMA-617",
          "type": "DRUG"
        },
        {
          "name": "68Ga-PSMA-PET scan/ MRI",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Quality of Life Questionnaires",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST",
        "BEHAVIORAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2025-10-27",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2025-11-04",
      "last_synced_at": "2026-05-21T23:49:28.745Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07223034"
    },
    {
      "nct_id": "NCT07416188",
      "title": "Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Glioblastoma",
        "Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype",
        "Relapsed Cancer",
        "Recurrent Tumor",
        "Glioblastoma Multiforme",
        "Recurring Glioblastoma",
        "Brain and Central Nervous System Tumors",
        "Glioma",
        "Glioblastomas",
        "Grade IV Astrocytoma",
        "GBM",
        "Recurrent Glioma (Glioblastoma Multiforme)",
        "High Grade Glioma",
        "Glioma, Malignant",
        "Brain Cancer"
      ],
      "interventions": [
        {
          "name": "LMP744",
          "type": "DRUG"
        },
        {
          "name": "Conventional Surgery or Biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 40,
      "start_date": "2026-05-25",
      "completion_date": "2032-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-20",
      "last_synced_at": "2026-05-21T23:49:28.745Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07416188"
    },
    {
      "nct_id": "NCT07349693",
      "title": "Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Recurrent Glioblastoma, IDH-Wildtype"
      ],
      "interventions": [
        {
          "name": "Cerebraca wafer",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide (for relapsed malignant glioma)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Everfront Biotech Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 175,
      "start_date": "2026-11-01",
      "completion_date": "2030-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-20",
      "last_synced_at": "2026-05-21T23:49:28.745Z",
      "location_count": 1,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07349693"
    },
    {
      "nct_id": "NCT06118723",
      "title": "The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Glioblastoma",
        "High-grade Glioma",
        "Glioblastoma, IDH-wildtype",
        "Glioblastoma, IDH-mutant",
        "Glioblastoma Multiforme, Adult",
        "Astrocytoma, Grade IV",
        "Astrocytoma, Grade III",
        "Astrocytoma, Malignant",
        "Brain Neoplasms",
        "Brain Neoplasm, Primary",
        "Brain Neoplasms, Adult",
        "Brain Neoplasm, Malignant"
      ],
      "interventions": [
        {
          "name": "Supramaximal resection",
          "type": "PROCEDURE"
        },
        {
          "name": "Maximal safe resection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Jasper Gerritsen",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 784,
      "start_date": "2022-01-01",
      "completion_date": "2028-01-01",
      "has_results": false,
      "last_update_posted_date": "2024-02-22",
      "last_synced_at": "2026-05-21T23:49:28.745Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Boston, Massachusetts",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06118723"
    },
    {
      "nct_id": "NCT06641908",
      "title": "Anti-GD2 ADC M3554 in Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "M3554",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono Research & Development Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2024-11-08",
      "completion_date": "2027-04-16",
      "has_results": false,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-05-21T23:49:28.745Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • New York, New York • Houston, Texas",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06641908"
    },
    {
      "nct_id": "NCT00003409",
      "title": "Motexafin Gadolinium Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "motexafin gadolinium",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1998-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2009-02-09",
      "last_synced_at": "2026-05-21T23:49:28.745Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Sacramento, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003409"
    }
  ]
}